Scientific Advisory Board

Dr. Francesco Marincola – MD

Dr. Marincola is considered one of the worlds leading tumor Immunologists. He was the Chief of the Infectious Disease and Immunogenetics Section in the Department of Transfusion Medicine at the Clinical Center of the National Institute of Health in Bethesda. He was founder and serves as Editor-in-Chief, Journal of Translational Medicine and ASHI Quarterly, senior editor for the Journal of the American Society for Histocompatibility and Immunogenetics, and editor for a variety of academic journals, including Immunotherapy, Journal of Immunotherapy, Journal of Immunology, Tumori, Clinical Cancer Research, Biological Therapy, and Cancer Immunology and Immunotherapy. He is also a founding member of the Society for Immunotherapy of Cancer.

Dr. Marincola has done extensive research in tumor immunology by developing strategies for studying tumor-host interactions in the context of human genetic polymorphism and cancer heterogeneity. During his tenure as a Senior Staff Scientist with the NCI Surgery Branch, Dr. Marincola investigated the identification of the algorithm responsible for tumor rejection by immune cells particularly in the context of metastatic melanoma. In particular, the focus of his research is the optimization of strategies to study clinical material during the conduct of clinical trials. The NIH Immunogenetics laboratory is recognized nationally and internationally for the cutting edge technologies applied for the study of genetic materials at the genomic, transcriptional, epigenetic and mutational level.

Dr. Vijay Mahant, MS, PhD

Dr. Mahant graduated from LUT in the United Kingdom and received his second post-doctorate from MD Anderson in Houston TX.  Dr. Mahant is a scientist with over 30 years of experience in immune and molecular diagnostics.  He has held executive positions and he is founder/co-founder of diagnostic companies with diverse experiences in Research and Development including Auto Genomics, Medi-Lite and Qualigen. He is the inventor of the “New Generation” ultra-sensitive TSH test for prostate cancer.

Dr. Mahant’s work can be seen all over the world in leading cancer institutions using his cutting edge genetic and diagnostic equipment. He has been on the forefront of the liquid biopsy and circulating tumor cell movement. His passion is to find ways to match tumors with specific drugs that might be off label and to create even better early detection diagnostic tests.

Dr. Phillip S. Kim PhD.

Dr. Kim was awarded the human genetics fellowship by the National Institute of Health (NIH) at the  Cedar Sinai Medical Center. His research focused on the development of gene-therapy model via hematopoietic-stem cell mediated gene transfer and the development of ‘Geno-dynamics’ system to investigate gene function.

At Prometheus he led oncology and gastroenterology research teams to develop technologies, platforms and services for personalized/ targeted diagnostic applications with prognostic, predictive and monitoring utilities for oncology and autoimmune diseases.

His work included  managing planning & execution of technical projects, clinical trials, science and technology communications, research collaborations & KOL (Key Opinion Leader) relationships, and publications.

He is the inventor of the immune pod which is positioned to address critical unmet need in oncology clinic by activating patient’s autologous immune cells specific for individual’s tumor for effective and safe cellular therapy without complex cellular manipulation. Minimally invasive approach using ‘Immuno-Pod’ maximizes tumor specific immune cell activation by exposing otherwise inaccessible tumor in vivo to contiguous ‘synthetic met’ ex vivo seamlessly integrated for each patient.

Dr. Kim’s valuable insight at TAM Center will help guide decisions for precision medicine and specific immune response for all patients.

Michael N. Liebman, Ph.D.

Michael N. Liebman, Ph.D. is the Managing Director of IPQ Analytics, LLC and of Strategic Medicine, Inc, and Strategic Medicine, BV (the Hague, NL) after serving as the Executive Director of the Windber Research Institute from 2003-2007.  He is also an Adjunct Professor of Pharmacology and Physiology at Drexel College of Medicine and Adjunct Professor of Drug Discovery at First Hospital of Wenzhou Medical University.  Previously, he was Director, Computational Biology and Biomedical Informatics at the University of Pennsylvania Cancer Center from 2000-2003.  He served as Global Head of Computational Genomics at Roche Pharmaceuticals and Director of Bioinformatics and Pharmacogenomics at Wyeth Pharmaceuticals, and Director of Genomics for Vysis, Inc.  He co-founded Prosanos, Inc (now United BioSource) (2000). He was on the faculty of Mount Sinai School of Medicine in Pharmacology and Physiology/Biophysics.   He serves on 14 scientific advisory boards and is on the Board of Directors and chairs the Science Committee of the Nathaniel Adamczyk Foundation for Pediatric ARDS and is an Advisor to the American Heart Association Science and Technology Accelerator.  

Michael is Chair of the Informatics Program of the PhRMA Foundation, Chair of its new program in Translational Medicine and Therapeutics, and a PhRMA Scientific Advisory Board member.  He is on the Advisory Board of the International Society for Translational Medicine and on the Editorial Board for the Journal of Translational Medicine, for Clinical and Translational Medicine and for Molecular Medicine and Therapeutics and the International Park for Translational Biomedicine (Shanghai).  He is an Invited Professor at the Shanghai Center for Bioinformatics Technology.  His research focuses on computational models of disease progression stressing risk detection, disease process and pathway modeling and analysis of lifestyle interactions and causal biomarker discovery and focuses on moving bedside problems into the research laboratory to improve patient care and quality of life.  Recent activities also include computational approaches to disease modeling, patient and disease stratification, drug safety, animal testing reduction, genomic data use in healthcare, and qualitative and quantitative risk assessment in healthcare and the life sciences.

Dr. Marincola has done extensive research in tumor immunology by developing strategies for studying tumor-host interactions in the context of human genetic polymorphism and cancer heterogeneity. During his tenure as a Senior Staff Scientist with the NCI Surgery Branch, Dr. Marincola investigated the identification of the algorithm responsible for tumor rejection by immune cells particularly in the context of metastatic melanoma. In particular, the focus of his research is the optimization of strategies to study clinical material during the conduct of clinical trials. The NIH Immunogenetics laboratory is recognized nationally and internationally for the cutting edge technologies applied for the study of genetic materials at the genomic, transcriptional, epigenetic and mutational level.

Francisco Silva

Mr. Silva currently serves as Vice President of Research and Development for the publicly traded company BioRestorative Therapies (Nasdaq: BRTX), where he leads the development of clinical-stage adult stem cell therapeutics for disc degeneration. BRTX-100 is currently approved for an FDA Phase 2 clinical trial to treat chronic lumbar disc disease. 

In addition, Mr. Silva discovered and is commercially developing brown fat stem cells under BioRestorative’s ThermoStemTM program. Mr. Silva helped start and grow several companies in the regenerative medicine space, including PrimeGen Biotech, Medistem Inc, and Batu Biologics. 

Mr. Silva has 20 years of experience developing novel cell lines and has several publications and issued patents covering the development and therapeutic uses of cell-based technologies.

Contact Us